Considering that 80% of clinical trials run behind schedule, it pays to look hard from the outset at the sites you engage to conduct your study. Too often, sponsors rely on traditional methods of site selection by working within limited data sets that do not yield positive trial results.
Schedule a WCG Consultation to discover how leading sponsors and CROs are using the WCG Knowledge Base™ to improve speed and the probability of success for clinical trials via deep intelligence on investigators and live studies.
The Portfolio Optimization Strategy & Planning Consultation is a 1-hour session, led by our experts. During this interactive session we’ll use real-time data to answer your key study questions. You’ll gain valuable insights you can immediately use to drive greater success for your current or upcoming programs. Upon registration for your session, you can submit a current or upcoming study of concern, which we’ll analyze during our meeting.
Gain valuable insights from the industry's most comprehensive knowledge base
SiteView is part of the WCG Knowledge Base: our proprietary decision engine with trusted, FDA-validated data on 95% of all industry-sponsored research, enrollment performance on 85% of all FDA-regulated investigators, and demographic and performance metrics for more than 140,000 global investigators.
With the WCG Knowledge Base, our clients and partners are accelerating their clinical trial timelines thanks to intelligent, data-driven decisions in each phase of the clinical trial.
Find your study’s best-match sites
Many of our Sponsor clients are actively updating and/or expanding their site networks to better align to their study execution. Our Site Matching module aligns our proprietary Site- and Investigator-based study execution data against your planned and active studies to provide a more strategic alignment against your full portfolio. Engaging with your best-fit sites dramatically improves your likelihood of success.
See competitive landscape at each site
Many sponsors and CROs are unaware of the number of studies currently being executed at their selected sites. SiteView provides a cricital view into the competitive landscape at each site, letting you pro-actively adjust or augment your site selection to meet your enrollment goals and timelines.
Uncover investigator study concentration
SiteView can show you the number of open studies investigators are running, by therapeutic area. Knowing study concentration at the investigator level proves invaluable in planning and enrollment management, as many investigators have limited resources to effectively handle concurrent studies in the same therapeutic area.
Featured experts from our Portfolio Optimization Strategy & Planning team
Nicholas Slack, MBE
EVP & Chief Commercial Officer, WCG
Lindsay McNair, MD, MPH, MSB
Chief Medical Officer, WCG
President, Site Activation, WCG
Jeff Litwin, MD
Chief Operating Officer,
Jonathan Zung, Ph.D.
President, Clintrax and Advisor to CEO, WCG
Vice President, Clinical Solutions, WCG
Linda Sullivan, MBA
Co-Founder & Executive Director, Metrics Champion Consortium
Mark G. A. Opler, PhD, MPH
Chief Research Officer, WCG MedAvante-ProPhase
Sofija Jovic, PhD, MBA
Business Transformation Advisor, WCG MedAvante-ProPhase
Request a Portfolio Optimization Strategy & Planning Consultation
Ready to to see how the investigators in your current or planned studies match up against the historic performance of all available investigators for the therapeutic area of the study?
Complete the form to schedule a consultation with WCG. We’ll share benchmark data from the WCG Knowledge Base, analyze your results, and share some of the common practices of top performers.